Diabetic autonomic neuropathy

Handbook of Clinical Neurology

Volumn 117, Issue , 2013, Pages 279-294

  Vinik, Aaron I ^a   Erbas, Tomris ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cardiovascular risk prediction; Central dopaminergic dysfunction; Imbalance; Parasympathetic; Potential for prevention and restoration of balance; Sympathetic; Time and frequency domain analysis

Indexed keywords

AUTONOMIC NEUROPATHY; CARDIOVASCULAR RISK PREDICTION; CENTRAL DOPAMINERGIC DYSFUNCTION; DIABETIC NEUROPATHY; HUMAN; IMBALANCE; PARASYMPATHETIC; POTENTIAL FOR PREVENTION AND RESTORATION OF BALANCE; REVIEW; SYMPATHETIC; TIME AND FREQUENCY DOMAIN ANALYSIS; AUTONOMIC NERVOUS SYSTEM DISEASES; COMPLICATION;

CARDIOVASCULAR RISK PREDICTION; CENTRAL DOPAMINERGIC DYSFUNCTION; IMBALANCE; PARASYMPATHETIC; POTENTIAL FOR PREVENTION AND RESTORATION OF BALANCE; SYMPATHETIC; TIME AND FREQUENCY DOMAIN ANALYSIS;

AUTONOMIC NERVOUS SYSTEM DISEASES; DIABETIC NEUROPATHIES; HUMANS;

EID: 84884963199     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-53491-0.00022-5     Document Type: Chapter

References (113)

1. Airaksinen K.E.J., Koistinen M.J. Association between silent coronary artery disease, diabetes, and autonomic neuropathy: fact or fallacy?. Diabetes Care 1992, 15:288-292.
2. Albers A.R., Krichavsky M.Z., Balady G.J. Stress testing in patients with diabetes mellitus: diagnostic and prognostic value. Circulation 2006, 113:583-592.
3. Ambepityia G., Kopelman P.G., Ingram D., et al. Exertional myocardial ischemia in diabetes: a quantitative analysis of anginal perceptual threshold and the influence of autonomic function. J Am Coll Cardiol 1990, 15:72-77.
4. Astrup A.S., Tarnow L., Rossing P., et al. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006, 29:334-339.
5. Azad N., Emanuele N.V., Abraira C., et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J Diabetes Complications 1999, 13:307-313.
6. Battle W.M., Snape W.J., Alavi A., et al. Colonic dysfunction in diabetes mellitus. Gastroenterology 1980, 79:1217-1221.
7. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992, 15:1835-1843.
8. Burger A.J., Weinrauch L.A., D'Elia J.A., et al. Effects of glycemic control on heart rate variability in type I diabetic patients with cardiac autonomic neuropathy. Am J Cardiol 1999, 84:687-691.
9. Burgos L.G., Ebert T.J., Assiddao C., et al. Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy. Anesthesiology 1989, 70:591-597.
10. Buse J.B., Bigger J.T., Byington R.P., et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007, 99:21i-33i.
11. Calles-Escandon J., Lovato L., Simons-Morton D., et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics. Diabetes Care 2010, 33:721-727.
12. Cameron N., Cotter M. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997, 46:S31-S37.
13. Canto J.G., Shlipak M.G., Rogers W.J., et al. Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. JAMA 2000, 283:3223-3229.
14. Colberg S., Swain D., Vinik A. Use of heart rate reserve and rating of perceived exertion to prescribe exercise intensity in diabetic autonomic neuropathy. Diabetes Care 2003, 26:986-990.
15. DCCT EDIC Research Group Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. JAMA 2003, 290:2159-2167.
16. Diabetes Control and Complications Trial Research Group The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995, 122:561-568.
17. Diabetes Control and Complications Trial Research Group The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998, 41:416-423.
18. Didangelos T.P., Arsos G.A., Karamitsos D.T., et al. Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. J Diabetes Complications 2006, 20:1-7.
19. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
20. Erbas T., Varoglu E., Erbas B., et al. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 1993, 16:1511-1514.
21. Ewing D.J., Clarke B.F. Diabetic autonomic neuropathy: present insights and future prospects. Diabetes Care 1986, 9:648-665.
22. Ewing D.J., Boland O., Neilson J.M., et al. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patient. Diabetologia 1991, 34:182-185.
23. Freeman R. Diabetic autonomic neuropathy: an overview. Clinical Management of Diabetic Neuropathy 1998, 181-208. Humana Press, Totowa, NJ. A. Veves (Ed.).
24. Freeman R. Cardiovascular autonomic neuropathy. Diabetic Neuropathy 1999, 541-554. WB Saunders, Philadelphia. 2nd edn. P.J. Dyck, P.K. Thomas (Eds.).
25. Gaede P., Vedel P., Parving H.H., et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. Lancet 1999, 353:617-622.
26. Gerritsen J., Dekker J.M., TenVoorde B.J., et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care 2001, 24:1793-1798.
27. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
28. Greene D.A., Lattimer S.A. Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozocin diabetes and its correction by dietary myo-inositol supplementation. J Clin Invest 1983, 72:1058-1063.
29. Greene D.A., Lattimer S.A., Sima A.A. Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy?. Diabetes 1988, 37:688-693.
30. Hilsted J., Parving H.H., Christensen N.J., et al. Hemodynamics in diabetic orthostatic hypotension. J Clin Invest 1981, 68:1427-1434.
31. Hoeldtke R.D., Bryner K.D., McNeil D.R., et al. Nitrosative stress, uric acid, and peripheral nerve function in early type 1 diabetes. Diabetes 2002, 51:2817-2825.
32. Horowitz M., Edelbroek M., Fraser R. Disordered gastric motor function in diabetes mellitus. Recent insights into prevalence, pathophysiology, clinical relevance and treatment. Scand J Gastroenterol 1991, 26:673-684.
33. Horrobin D.F. Essential fatty acids in the management of impaired nerve function in diabetes. Diabetes 1997, 46(Suppl 2):S90-S93.
34. Janssens J., Peeters T.L., Vantrappen G. Improvement of gastric emptying in diabetic gastroparesis by erthromycin. N Engl J Med 1990, 322:1028-1031.
35. Jin H.Y., Kang Y.M., Kim C.Y., et al. Morphological comparison of small nerve fibres in gastric mucosa in non-diabetic and type 2 diabetic subjects. Diabet Med 2009, 26:943-946.
36. Kahn J.K., Sisson J.C., Vinik A.I. Prediction of sudden cardiac death in diabetic autonomic neuropathy. J Nucl Med 1988, 29:1605-1606.
37. Katz A., Liberty I.F., Porath A., et al. A simple bedside test of 1-minute heart rate variability during deep breathing as a prognostic index after myocardial infarction. Am Heart J 1999, 138:32-38.
38. Kellogg A.P., Converso K., Wiggin T., et al. Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes. Am J Physiol Heart Circ Physiol 2009, 296:H453-H461.
39. Langer A., Freeman M.R., Josse R.G., et al. Detection of silent myocardial ischemia in diabetes mellitus. Am J Cardiol 1991, 67:1073-1078.
40. Lee K.H., Jang H.J., Kim Y.H., et al. Prognostic value of cardiac autonomic neuropathy independent and incremental to perfusion defects in patients with diabetes and suspected coronary artery disease. Am J Cardiol 2003, 92:1458-1461.
41. Levitas I.M., Kristal J.J. Stress exercise testing of the young diabetic for the detection of unknown coronary artery disease. Isr J Med Sci 1972, 8:845-847.
42. Licht C.M., Vreeburg S.A., van Reedt Dortland A.K., et al. Increased sympathetic and decreased parasympathetic activity rather than changes in hypothalamic-pituitary-adrenal axis activity is associated with metabolic abnormalities. J Clin Endocrinol Metab 2010, 95:2458-2466.
43. Low P.A., Nickander K.K., Tritschler H.J. The roles of oxidative stress and antioxidant treatment in experimental diabetic neuropathy. Diabetes 1997, 46(Suppl 2):S38-S42.
44. Lykke J.A., Tarnow L., Parving H.H., et al. A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes. Scand J Clin Lab Invest 2008, 68:654-659.
45. Ma J., Rayner C.K., Jones K.L., et al. Diabetic gastroparesis: diagnosis and management. Drugs 2009, 69:971-986.
46. Marchant B., Umachandran V., Stevenson R., et al. Silent myocardial ischemia: role of subclinical neuropathy in patients with and without diabetes. J Am Coll Cardiol 1993, 22:1433-1437.
47. Margolis J.R., Kannel W.S., Feinleib M., et al. Clinical features of unrecognized myocardial infarction - silent and symptomatic. Eighteen year follow-up: the Framingham Study. Am J Cardiol 1973, 32:1-7.
48. Maser R., Lenhard M., DeCherney G. Cardiovascular autonomic neuropathy: the clinical significance of its determination. Endocrinologist 2000, 10:27-33.
49. Maser R.E., Mitchell B.D., Vinik A.I., et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 2003, 26:1895-1901.
50. Mathias C.J., Da Coata D.F., Fosbraey P. Hypotensive and sedative effects of insulin in autonomic failure. Br Med J 1987, 295:161-163.
51. Matsuki A., Nozawa T., Igarashi N., et al. Fluvastatin attenuates diabetes-induced cardiac sympathetic neuropathy in association with a decrease in oxidative stress. Circ J 2010, 74:468-475.
52. McCulloch D.K., Campbell I.W., Wu F.C., et al. The prevalence of diabetic impotence. Diabetologia 1980, 18:279-283.
53. Miettinen H., Lehto S., Salomaa V., et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998, 21:69-75.
54. Muenter S.N., Charkoudian N., Dotson R.M., et al. Baroreflex control of muscle sympathetic nerve activity in postural orthostatic tachycardia syndrome. Am J Physiol Heart Circ Physiol 2005, 289:H1226-H1233.
55. Nagamachi S., Fujita S., Nishii R., et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol 2006, 13:34-42.
56. Neil H.A., Thompson A.V., John S., et al. Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically define population. Diabet Med 1989, 6:20-24.
57. O'Brien I.A., O'Hare J.P., Lewin I.G., et al. The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. Q J Med 1986, 61:957-967.
58. O'Brien I.A., McFadden J.P., Corrall R.J. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med 1991, 79:495-502.
59. Obrosova I.G. How does glucose generate oxidative stress in peripheral nerve?. Int Rev Neurobiol 2002, 50:3-35.
60. Orchard T.J., Lloyd C.E., Maser R.E., et al. Why does diabetic autonomic neuropathy predict IDDM mortality? An analysis from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Res Clin Pract 1996, 34:S165-S171.
61. Pacher P., Liaudet L., Soriano F., et al. The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 2002, 51:514-521.
62. Page M.M., Watkins P.J. Provocation of postural hypotension by insulin in diabetic autonomic neuropathy. Diabetes 1976, 25:90-95.
63. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
64. Pfeifer M.A., Weinberg C.R., Cook D.L., et al. Autonomic neural dysfunction in recently diagnosed diabetic subjects. Diabetes Care 1984, 7:447-453.
65. Pittenger G.L., Malik R.A., Burcus N., et al. Specific fiber deficits in sensorimotor diabetic polyneuropathy correspond to cytotoxicity against neuroblastoma cells of sera from patients with diabetes. Diabetes Care 1999, 22:1839-1844.
66. Pop-Busui R., Low P.A., Waberski B.H., et al. Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC). Circulation 2009, 119:2886-2893.
67. Pop-Busui R., Evans G., Gerstein H., et al. Effects of cardiac autonomic dysfunction on mortality risk in the action to control cardiovascular risk in diabetes (ACCORD) trial. Diabetes Care 2010, 33:1578-1584. ACCORD Study Group.
68. Purewal T., Watkins P.J. Postural hypotension in diabetic neuropathy: a review. Diabetic Med 1995, 12:192-200.
69. Rathmann W., Ziegler D., Jahnke M., et al. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993, 10:820-824.
70. Rendell M.S., Rajfer J., Wicker P.A., et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA 1999, 281:421-426.
71. Rennings A.J., Smits P., Stewart M.W., et al. Autonomic neuropathy predisposes to rosiglitazone-induced vascular leakage in insulin-treated patients with type 2 diabetes: a randomised, controlled trial on thiazolidinedione-induced vascular leakage. Diabetologia 2010, 53:1856-1866.
72. Rosen S.D., Camici P.G. The brain-heart axis in the perception of cardiac pain: the elusive link between ischaemia and pain. Ann Med 2000, 32:350-364.
73. Roy T.M., Peterson H.R., Snider H.L. Autonomic influence on cardiovascular performance in diabetic subjects. Am J Med 1989, 87:382-388.
74. Selim M.M., Wendelschafer-Crabb G., Redmon J.B., et al. Gastric mucosal nerve density: a biomarker for diabetic autonomic neuropathy?. Neurology 2010, 75:973-981.
75. Shakespeare C.F., Katritsis D., Crowther A., et al. Differences in autonomic nerve function in patients with silent and symptomatic myocardial ischaemia. Br Heart J 1994, 71:22-29.
76. Singer W., Spies J.M., McArthur J., et al. Prospective evaluation of somatic and autonomic small fibers in selected autonomic neuropathies. Neurology 2004, 62:612-618.
77. Stansberry K.B., Shapiro S.A., Hill M.A., et al. Impaired peripheral vasomotion in diabetes. Diabetes Care 1996, 19:715-721.
78. Stansberry K.B., Hill M.A., Shapiro S.A., et al. Impairment of peripheral blood flow responses in diabetes resembles an enhanced aging effect. Diabetes Care 1997, 20:1711-1716.
79. Stansberry K.B., Peppard H.R., Babyak L.M., et al. Primary nociceptive afferents mediate the blood flow dysfunction in non-glabrous (hairy) skin of type 2 diabetes: a new model for the pathogenesis of microvascular dysfunction. Diabetes Care 1999, 22:1549-1554.
80. Stevens M., Dayanikli F., Raffel D., et al. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy. J Am Coll Cardiol 1998, 31:1575-1584.
81. Stevens M., Raffel D., Allman K.C., et al. Cardiac sympathetic dysinnervation in diabetes implications for enhanced cardiovascular risk. Circulation 1998, 98:961-968.
82. Stevens M., Raffel D., Allman K., et al. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. Metabolism 1999, 48:92-101.
83. Stewart J.M., Munoz J., Weldon A. Clinical and physiological effects of an acute alpha-1 adrenergic agonist and a beta-1 adrenergic antagonist in chronic orthostatic intolerance. Circulation 2002, 106:2946-2954.
84. Stewart J.M., Medow M.S., Montgomery L.D. Local vascular responses affecting blood flow in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol 2003, 285:H2749-H2756.
85. Stewart J.M., Montgomery L.D. Regional blood volume and peripheral blood flow in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol 2004, 287:H1319-H1327.
86. Storstein L., Jervell J. Response to bicycle exercise testing in long-standing juvenile diabetes. Acta Med Scand 1979, 205:227-230.
87. Sturm A., Holtmann G., Goebell H., et al. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 1999, 60:422-427.
88. Suarez G.A., Clark V.M., Norell J.E., et al. Sudden cardiac death in diabetes mellitus: risk factors in the Rochester Diabetic Neuropathy Study. J Neurol Neurosurg Psychiatry 2005, 76:240-245.
89. Sundkvist G., Hillarp B., Lilja B., et al. Esophageal motor function evaluated by scintigraphy, video-radiography and manometry in diabetic patients. Acta Radiol 1989, 30:17-19.
90. Sundkvist G., Lind P., Bergstrom B., et al. Autonomic nerve antibodies and autonomic nerve function in type 1 and type 2 diabetic patients. J Intern Med 1991, 229:505-510.
91. Veglio M., Borra M., Stevens L.K., et al. The relation between QTc interval prolongation and diabetic complications. The EURODIAB IDDM Complications Study Group. Diabetologia 1999, 42:68-75.
92. Veves A., King G. Can VEGF reverse diabetic neuropathy in human subjects?. J Clin Invest 2001, 107:1215-1218.
93. Vinik A.I., Erbas T. Recognizing and treating diabetic autonomic neuropathy. Cleve Clin J Med 2001, 68:928-944.
94. Vinik A., Erbas T. Neuropathy. Handbook of Exercise in Diabetes 2002, 463-495. American Diabetes Association, Alexandria, VA. N. Ruderman, J.T. Devlin, S. Schneider (Eds.).
95. Vinik A.I., Milicevic Z. Recent advances in the diagnosis and treatment of diabetic neuropathy. Endocrinologist 1996, 6:443-461.
96. Vinik A.I., Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007, 115:387-397.
97. Vinik A., Erbas T., Pfeifer M.A. Diabetic autonomic neuropathy. Mc Graw Hill 2003, 2002:789-804. Diabetes Mellitus, Ellenberg & Rifkin's. 6th edn. D. Porte, R.S. Sherwin, A. Baron (Eds.).
98. Vinik A.I., Maser R.E., Mitchell B.D., et al. Diabetic autonomic neuropathy. Diabetes Care 2003, 26:1553-1579.
99. Vinik A.I., Maser R.E., Ziegler D. Neuropathy: the crystal ball for cardiovascular disease?. Diabetes Care 2010, 33:1688-1690.
100. Vinik A., Maser R., Ziegler D. Autonomic imbalance: prophet of doom or scope for hope?. Diabetic Med 2011, 28:643-651.
101. Wackers F.J., Young L.H., Inzucchi S.E., et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD Study. Diabetes Care 2004, 27:1954-1961.
102. Weber F., McCallum R. Gastric motor disorders. Consultations in Gastroentelogy 1996, 247-259. WB Saunders, Philadelphia. W.J. Snape (Ed.).
103. Winocour P.H., Dhar H., Anderson D.C. The relationship between autonomic neuropathy and urinary sodium and albumin excretion in insulin-treated diabetics. Diabet Med 1986, 3:436-440.
104. Wirta O., Pasternack A., Mustonen J., et al. Renal and cardiovascular predictors of 9 year total and sudden cardiac mortality in non-insulin-dependent diabetic subjects. Nephrol Dial Transplant 1997, 12:2612-2617.
105. Witte D.R., Tesfaye S., Chaturvedi N., et al. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005, 48:164-171.
106. Young L.H., Wackers F.J., Chyun D.A., et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD Study: a randomized controlled trial. JAMA 2009, 301:1547-1555.
107. Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis and treatment. Diabetes Metab Rev 1994, 10:339-383.
108. Ziegler D., Gries F.A., Spuler M., et al. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. J Diabetes Complications 1992, 6:49-57.
109. Ziegler D., Schatz H., Conrad F., et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 1997, 20:369-373.
110. Ziegler D., Weise F., Langen K.J., et al. Effect of glycaemic control on myocardial sympathetic innervation assessed by metaiodobenzylguanidine scintigraphy: a 4-year prospective study in IDDM patients. Diabetologia 1998, 41:443-451.
111. Ziegler D., Zentai C., Perz S., et al. Diminished heart rate variability (HRV) and prolonged QTc interval, but not increased QT dispersion (QTD) are predicators of mortality in the diabetic population. Diabetes 2004, 53:A57.
112. Ziegler D., Zentai C., Perz S., et al. Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general population. Exp Clin Endocrinol Diabetes 2006, 114:153-159.
113. Ziegler D., Zentai C.P., Perz S., et al. Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study. Diabetes Care 2008, 31:556-561.